Celyad (Formally Known as Cardio3 BioSciences)
Parc de L’Alliance
9, Boulevard de France
Braine - L’Alleud
1420
Tel: 32-2-790-35-30
Fax: 32-2-790-35-35
Website: http://www.cardio3.net/
Email: info@cardio3.net
134 articles with Celyad (Formally Known as Cardio3 BioSciences)
-
Celyad Oncology to announce full year 2022 financial results and host conference call
3/17/2023
Celyad Oncology announced that the Company will report full year 2022 financial and operating results on the evening of Thursday, March 23rd.
-
Celyad Oncology announces the publication of data from its Phase 1 THINK study of CYAD-01
2/9/2023
Celyad Oncology announces the publication of the data from the haematological arm of the THINK study which evaluated CYAD-01 in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma patients.
-
Celyad Oncology provides an update on its strategic business model, continuing to focus on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property
12/21/2022
Celyad Oncology, a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell therapies, provides an update on its Celyad 2.0 business strategy which has been adopted and implemented over the last few months.
-
Celyad Oncology Announces Third Quarter 2022 Financial Results and Recent Business Highlights
11/10/2022
Celyad Oncology SA provided an update on its financial results and recent business developments for the fiscal quarter ended September 30, 2022.
-
Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction
9/20/2022
Cellistic and Celyad Oncology announced a transaction whereby Cellistic will acquire Celyad Oncology’s Good Manufacturing Practice grade cell therapy manufacturing capability, including the existing facility and all related personnel.
-
The FDA has had a busy week, accepting drug applications, approving clinical trials and granting various special designations for Gamida Cell, Cellectis, Scynexis & more.
-
The FDA has placed a clinical hold on Beam Therapeutics' leukemia/lymphoma therapy and has lifted the hold on Celyad's CAR-T candidate for colorectal cancer.
-
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
5/31/2022
Celyad Oncology SA, a clinical-stage biotechnology company focused on the discovery and the development of Chimeric Antigen Receptor T cell therapies for cancer, announced that 350 registered shares benefit from a double voting right as of May 25, 2022.
-
Patient deaths associated with Astellas Pharma’s gene therapy candidate underscore the risks of developing potential one-and-done treatment options for serious diseases.
-
Belgium-based Celyad Oncology voluntarily paused a clinical trial with Merck after two deaths. Getting CAR T therapies to work in solid tumors has proven to be a difficult challenge.
-
Celyad announced that it is voluntarily pausing a clinical trial it’s conducting with Merck after reports of two patient deaths.
-
Biopharma and life sciences companies from across the globe provide updates to their businesses and pipelines.
-
CEO to CEO: Tips for First-time Founders
1/11/2022
BioSpace picked the brains of 10 biotech CEOs and founders, to solicit their advice for first-time founders. -
Celyad is focusing on advancing chimeric antigen receptor T cell (CAR T) therapies.
-
Celyad Oncology is at the forefront of cutting-edge immunotherapy and is hopeful of providing a new way forward for patients with relapsed/refractory multiple myeloma.
-
Clinical Catch-Up: May 31-June 5
6/8/2020
As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look. -
BioSpace Movers & Shakers, June 5
6/5/2020
Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers. -
The American Society of Clinical Oncology 2020 meeting was held virtually this year due to the COVID-19 pandemic. As usual, there were literally hundreds of abstracts, posters and presentations. Here’s a look at some of the highlights.
-
BioSpace Movers & Shakers, May 8
5/8/2020
Pharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
BioSpace Movers & Shakers, March 6
3/6/2020
Life sciences and pharma companies from across the globe strengthen their leadership teams and board with this week's Movers & Shakers.